**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**ESPS Manuscript NO: 29555**

**Manuscript Type: Minireviews**

**Overdiagnosis of gastric cancer by endoscopic screening**

Hamashima C. Endoscopic screening overdiagnosis

**Chisato Hamashima**

**Chisato Hamashima,** Division of Cancer Screening Assessment and Management, Center for Public Health Science, National Cancer Center, Tokyo 104-0045, Japan

**Author contributions:** Hamashima C designed and performed the recently published research studies cited in thisminireview.

**Supported by** Grant-in-Aid for Scientific Research, Japan by the Japanese Society for the Promotion of Science, Tokyo, Japan, No. 26460620.

**Conflict-of-interest statement:** The author has no conflicts of interest to report.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Chisato Hamashima,** Division of Cancer Screening Assessment and Management, Center for Public Health Science, National Cancer Center, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan. [chamashi@ncc.go.jp](mailto:chamashi@ncc.go.jp)

**Telephone:** +81-3-35475305

**Fax:** +81-3-35478587

**Received:** August 19, 2016

**Peer-review started:** August 21, 2016

**First decision:** September 28, 2016

**Revised:** November 22, 2016

**Accepted:** December 7, 2016

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer screening using endoscopy has recently spread in Eastern Asian countries showing increasing evidence of its effectiveness. However, despite the benefits of endoscopic screening for gastric cancer, its major harms include infection, complications, false-negative results, false-positive results, and overdiagnosis. The most serious harm of endoscopic screening is overdiagnosis and this can occur in any cancer screening programs. Overdiagnosis is defined as the detection of cancers that would never have been found if there is no cancer screening. Overdiagnosis has been estimated fromrandomized controlled trials, observational studies, and modeling. It can be calculated on the basis of a comparison of the incidence of cancer between screened and unscreened individuals after the follow-up. Although the estimation method for overdiagnosis has not yet been standardized, estimation of overdiagnosis is needed in endoscopic screening for gastric cancer. To minimize overdiagnosis, the target age group and screening interval should be appropriately defined. Moreover, the balance of benefits and harms must be carefully considered to effectively introduce endoscopic screening in communities. Further research regarding overdiagnosis is warranted when evaluating the effectiveness of endoscopic screening.

**Key words:** Gastric cancer; Cancer screening; Upper gastrointestinal endoscopy; Overdiagnosis; Harm

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Overdiagnosis is the most serious harm of cancer screening and this can occur in any cancer screening programs. It is defined as the detection of cancers that would never have been found if there is no screening. Despite the lack of standardization of the estimation method for overdiagnosis, its estimation is necessary in endoscopic screening for gastric cancer. To minimize overdiagnosis, the target age group and screening interval should be appropriately defined. Consideration of the balance of benefits and harms of endoscopic screening is imperative for its effective introduction in communities.

Hamashima C. Overdiagnosis of gastric cancer by endoscopic screening. *World J Gastrointest Endosc* 2016; In press

**INTRODUCTION**

Endoscopic examination has been increasingly performed for gastric cancer screening in Eastern Asian countries[1]. Although national programs for gastric cancer screening have already been started in South Korea and Japan, endoscopic screening has been mainly performed in clinical settings as opportunistic screening[2]. Since 2000, endoscopic screening for gastric cancer has been performedin South Korea[3]. In 2016, the Japanese government decided to introduce endoscopic screening for gastric cancer as a national program based on the guidelines published by the National Cancer Center in Japan[4]. Although evidence for reduction in mortality from gastric cancer by endoscopic screening was insufficient when this method was initially introduced in South Korea, evidence regarding its effectiveness has gradually increased in South Korea, China, and Japan[5-8]. Gastric cancer screening by endoscopy has been increasingly anticipated because early stage cancer can be more definitively diagnosed than by radiographic screening using upper gastrointestinal series with barium meal.

Despite the benefits of endoscopic screening for gastric cancer, the major harms of this technique include infection, complications, false-negative results, false-positive results, and overdiagnosis[4]. Although complications and infection are highly probable in endoscopic screening, these can be minimized by appropriate safety management. On the other hand, false-positive results and overdiagnosis frequently occur in all cancer screenings. The false-positive rate can be managed using a quality assurance system to some extent[9]. However, because of the high sensitivity of endoscopic examination which can detect many early stage cancers, overdiagnosis cannot be avoided. To effectively introduce endoscopic screening in communities, the balance of benefits and harms should be prudently analyzed. Therefore, comprehensive knowledge of overdiagnosis in endoscopic screening is crucial as well as effective strategies for its management.

**BASIC CONCEPT OF OVERDIAGNOSIS**

When we consider the harms of endoscopic screening, overdiagnosis cannot be ignored because it occurs in this procedure and in all cancer screening programs[10]. Overdiagnosis represents the actual cancer detected by screening which would never have been found if there is no cancer screening. In cancer screening, it is not possible to distinguish between an overdiagnosis of cancer and a diagnosis of cancer that will progress[10]. Overdiagnosis leads to unnecessary examinations and treatments, the results of which can cause psychological problems[11].

Mammographic screening provides an easily understood example of the basic concept of overdiagnosis. Since the late 1990s, mammographic screening for breast cancer has rapidly spread nationwide in the United States. Women aged 40-69 years were the major target of mammographic screening. In Figure 1A, the upper graph shows a large impact of mammographic screening during the 1980s and early 1990s among women aged 40 years or older in the United States[12]. In the same Figure 1A, the lower graph shows a rapid increase in the incidence of early stage breast cancer according to the dissemination of mammographic screening. However, a small decrease in the incidence of late-stage breast cancer is observed.

In Figure 1B, breast cancer incidence flattened in women younger than 40 years of age because they did not have any opportunity to have mammographic screening. These trends of breast cancer in women aged 40 years and over suggested that the detected early stage cancer included cases of overdiagnosis.

There have also been developments of new techniques which can diagnose cancers that do not progress and are not fatal even if left untreated. The growth rates of cancer vary and are divided into 4 categories: Rapid, slow, very slow, and non-progressive. Periodic screening detects slow-growing (Tumor B) and non-progressive (Tumor A) cancers early, and finds some progressive cancer (Tumor C) early (Figure 2)[13]. Without screening, Tumor A remains undetectable and causes no morbidity during the patient’s lifetime. However, rapid-growing cancer (Tumor D) which is a fatal tumor cannot be screened earlier and may cause death even with treatment. The benefit of screening is limited to true-positive results when earlier treatment works better. Even if the screening result is true-positive, there are no benefits for Tumors A, D, and partly C[13]. When screening starts, this screening cascade cannot be stopped[14].

Overdiagnosis is not limited to the harms of cancer screening but it can occur in any diagnostic examinations. However, the frequency of overdiagnosis varies among examinations and diseases. The target of cancer screening is asymptomatic persons without any health problems. Therefore, in cancer screening, harms should be minimized and benefits should outweigh harms[14]. Importantly, the harms of cancer screening are often ignored because the screening benefits are usually emphasized. Although there is a possibility that endoscopic screening has made a large impact in terms of reducing mortality from gastric cancer, we have to consider minimizing its harms, particularly overdiagnosis. Therefore, estimation of the frequency of overdiagnosis is a key issue in considering the balance of benefits and harms of endoscopic screening.

**ESTIMATION OF OVERDIAGNOSIS**

Overdiagnosis has been estimated fromrandomized controlled trials (RCTs), ecological and cohort studies, pathological and imaging studies, and modeling[15]. The frequency of overdiagnosis is calculated on the basis of the difference in the incidence of cancer between screened and unscreened individuals after the follow-up. Although the estimation method has not yet been standardized, there is a high divergence, for example, 0%-50% in mammographic screening[16].

The frequency of overdiagnosis was previously estimatedon the basis of RCTs without the provision of mammographic screening at the end of the screening phases. In the Independent UK Panel on Breast Cancer Screening, the overdiagnosis rate was calculated from the Canadian and Malmo studies for mammographic screening using 4 methods with different denominators as follows (Figure 3)[16]: (1) excess cancers as the frequency of cancers diagnosed over the whole follow-up period in unscreened women; (2) excess cancers as the frequency of cancers diagnosed over the whole follow-up period in women invited for screening; (3) excess cancers as the frequency of cancers diagnosed during the screening period in women invited for screening; and (4) excess cancers as the frequency of cancers detected at screening in women invited for screening. The frequency of overdiagnosis was estimated to be higher when the follow-up periods were limited to the screening phases. In the conclusions, the overdiagnosis rate for mammographic screening was in the range of 10%-20% based on the estimation using the data from 2 RCTs. Recently, a Canadian study has reported an overdiagnosis frequency of 22% based on 25 years of follow-up[17].

On the other hand, ecological and cohort studies have been commonly used to estimate the frequency of overdiagnosis. These studies can directly answer questions in real world settings and compare results from different settings[15]. Carter et al. have suggested that ecological and cohort studies in multiple settings are the most appropriate approaches for qualifying and monitoring overdiagnosis in cancer screening programs[15].

**OVERDIAGNOSIS OF GASTRIC CANCER BY ENDOSCOPIC SCREENING**

The frequency of overdiagnosis of gastric cancer by endoscopic screening has not yet been estimated. Excess rate was calculated on the basis of the results of endoscopic screening for gastric cancer which indicated that the observed number of detected cancer was twice the expected number (Table 1)[18]. However, the excess cancers included both early detection cases which progress into fatal cancers and overdignosis cases.

The calculation of sensitivity is affected by the number of overdiagnosis cases. The detection method is the most common and simplest procedure for calculating sensitivity in which the numerator includes all detected cancers and the denominator is the sum of detected cancers and interval cancers. In the detection method, sensitivity is often overestimated, whereas in the incidence method, overdiagnosis cases can be avoided[19]. Sensitivity calculation by the incidence method was adopted in breast, lung, and colorectal cancer screenings[20-22]. In prevalence screening for using endoscopic screening for gastric cancer, the sensitivity was reportedly 0.955 (95%CI: 0.875-0.991) by the detection method and 0.886 (95%CI: 0.698-0.976) by the incidence method (Table 2)[23]. In incidence screening using endoscopic screening for gastric cancer, the sensitivity was reportedly 0.977 (95%CI: 0.919-0.997) by the detection method and 0.954 (95%CI: 0.842-0.994) by the incidence method[23]. The discrepancy between the results calculated by the detection method and the incidence method was small. It might be suggested that the frequency of overdiagnosis on endoscopic screening for gastric cancer is not very high.

**STRATEGIES FOR MANAGEMENT OF OVERDIAGNOSIS**

Although frequent screenings can diagnose numerous cancers, the possibility of including overdiagnosis is high. In actuality, frequent screenings easily result in overdiagonsis. Therefore, the appropriate number of screenings should be considered in endoscopic screening for gastric cancer. The American College of Physicians has recommended high-value care based on the value framework (Figure 4)[14,24]. The value of cancer screening is determined by a trade-off between benefits versus harms and costs. As the intensity increases, the benefits of screening rapidly increase. However, as the intensity increases beyond an optimal level, the benefits decrease whereas the harms and costs increase rapidly thereby reducing the value of cancer screening. High-value care has been recommended which is defined as the lowest intensity threshold. On the basis of this concept, high-value and low-value screening strategies have been developed for 5 types of cancer. This framework can be adopted in endoscopic screening for gastric cancer. Since endoscopic screening has a high sensitivity, it has the same problems. To minimize harms including overdiagnosis and to maximize the benefits, the target age group and screening interval should be appropriately clarified. To decrease the harms of unnecessary examinations and treatments, the “Choosing Wisely” campaign has rapidly expanded collaboration with academic societies in the United States and other countries[25]. The basic concepts of the ‘Choosing Wisely’ campaign are focused on the same goal of minimization of overdiagnosis of endoscopic screening for gastric cancer.

**CONCLUSION**

Overdiagnosis is the most serious harm of endoscopic screening for gastric cancer. Although the estimation method for the frequency of overdiagnosis has not yet been standardized, the present study is essential in further assessing the harms of endoscopic screening for gastric cancer in terms of overdiagnosis. To minimize overdiagnosis, the target age group and screening interval should be clearly defined in consideration of the balance of benefits and harms. Further research into overdiagnosis in endoscopic screening is warranted to realize its effective introduction in communities.

**ACKNOWLEDGEMENTS**

We are indebted to Dr. Edward F Barroga, Associate Professor and Senior Medical Editor of Tokyo Medical University for reviewing and editing the English manuscript. We also thank Ms. Kanoko Matsushima, Ms. Junko Asai, and Ms. Ikuko Tominaga for research assistance.

**REFERENCES**

1 **Leung WK**, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ. Screening for gastric cancer in Asia: current evidence and practice. *Lancet Oncol* 2008; **9**: 279-287 [PMID: 18308253 DOI: 10.1016/S1470-2045(08)70072-X]

2 **Goto R**, Hamashima C, Mun S, Lee WC. Why screening rates vary between Korea and Japan--differences between two national healthcare systems. *Asian Pac J Cancer Prev* 2015; **16**: 395-400 [PMID: 25684461]

3 **Kim Y**, Jun JK, Choi KS, Lee HY, Park EC. Overview of the National Cancer screening programme and the cancer screening status in Korea. *Asian Pac J Cancer Prev* 2011; **12**: 725-730 [PMID: 21627372]

4 **Hamashima C**. Benefits and harms of endoscopic screening for gastric cancer. *World J Gastroenterol* 2016; **22**: 6385-6392 [PMID: 27605874 DOI: 10.3748/wjg.v22.i28.6385]

5 **Hamashima C**, Shabana M, Okada K, Okamoto M, Osaki Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. *Cancer Sci* 2015; **106**: 1744-1749 [PMID: 26432528 DOI: 10.1111/cas.12829]

6 **Hamashima C**, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. *PLoS One* 2013; **8**: e79088 [PMID: 24236091 DOI: 10.1371/journal.pone.0079088]

7 **Cho B**. Evaluation of the validity of current national health screening programs and plans to improve the system. Seoul: Seoul University, 2013: 741-758 (in Korean)

8 **Chen Q**, Yu L, Hao CQ, Wang JW, Liu SZ, Zhang M, Zhang SK, Guo LW, Quan PL, Zhao N, Zhang YW, Sun XB. Effectiveness of endoscopic gastric cancer screening in a rural area of Linzhou, China: results from a case-control study. *Cancer Med* 2016; **5**: 2615-2622 [PMID: 27367362 DOI: 10.1002/cam4.812]

9 **Hamashima C**, Fukao A. Quality assurance manual of endoscopic screening for gastric cancer in Japanese communities. *Jpn J Clin Oncol* 2016 [PMID: 27589938 DOI: 10.1093/jjco/hyw106]

10 **Vainio H**, Bianchini F (eds.). IARC Handbooks of Cancer Presentation. Volume 7. Breast Cancer Screening. Lyon: IARC Press, 2002: 144-147

11 **Black WC**. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. *J Natl Cancer Inst* 2000; **92**: 1280-1282 [PMID: 10944539]

12 **Bleyer A**, Welch HG. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013; **368**: 677-679 [DOI: 10.1056/NEJMc1215494]

13 **Esserman L**, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. *JAMA* 2009; **302**: 1685-1692 [PMID: 19843904 DOI: 10.1001/jama.2009.1498]

14 **Harris RP**, Wilt TJ, Qaseem A. A value framework for cancer screening: advice for high-value care from the American College of Physicians. *Ann Intern Med* 2015; **162**: 712-717 [PMID: 25984846 DOI: 10.7326/M14-2327]

15 **Carter JL**, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. *BMJ* 2015; **350**: g7773 [PMID: 25569206 DOI: 10.1136/bmj.g7773]

16 **Marmot MG**, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer* 2013; **108**: 2205-2240 [PMID: 23744281 DOI: 10.1038/bjc.2013.177]

17 **Miller AB**, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. *BMJ* 2014; **348**: g366 [PMID: 24519768 DOI: 10.1136/bmj.g366]

18 **Hamashima C**, Sobue T, Muramatsu Y, Saito H, Moriyama N, Kakizoe T. Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program. *Jpn J Clin Oncol* 2006; **36**: 301-308 [PMID: 16735372 DOI: 10.1093/jjco/hyl022]

19 **Day NE**. Estimating the sensitivity of a screening test. *J Epidemiol Community Health* 1985; **39**: 364-366 [PMID: 4086970 DOI: 10.1136/jech.39.4.364]

20 **Fletcher SW**, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. *J Natl Cancer Inst* 1993; **85**: 1644-1656 [PMID: 8105098 DOI: 10.1093/jnci/85.20.1644]

21 **Zappa M**, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience. *Int J Cancer* 2001; **92**: 151-154 [PMID: 11279619 DOI: 10.1002/1097-0215(200102)9999: 9999<: AID-IJC1149>3.0.CO; 2-6]

22 **Toyoda Y**, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. *Br J Cancer* 2008; **98**: 1602-1607 [PMID: 18475292 DOI: 10.1038/sj.bjc.6604351]

23 **Hamashima C**, Okamoto M, Shabana M, Osaki Y, Kishimoto T. Sensitivity of endoscopic screening for gastric cancer by the incidence method. *Int J Cancer* 2013; **133**: 653-659 [PMID: 23364866 DOI: 10.1002/ijc.28065]

24 **Wilt TJ**, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. *Ann Intern Med* 2015; **162**: 718-725 [PMID: 25984847 DOI: 10.7326/M14-2326]

25 **ABIM Foundation**. Choosing Wisely. Available from: URL: http://www.choosingwisely.org/

**P-Reviewer:** Chrom P, El-Tawil AM, Soriano-Ursua MA **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Comparison of results from cohort studies of endoscopic screening for gastric cancer**


|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Target for cancer screening** | **Method** | **Male** |  |  |  | **Female** |  |  |
|  |  | **Observed number** | **Expected** | **O/E** |  | **Observed number** | **Expected number** | **O/E** |
| **number** |
| **Stomach** | **Endoscopy** | **28** | **15.31** | **1.83** |  | **7** | **3.69** | **1.9** |
| **Colon and** | **Barium enema** | **4** | **2.25** | **1.78** |  | **4** | **1.08** | **3.7** |
| **rectum** | **Total colonoscopy** | **26** | **21.9** | **1.19** |  | **15** | **7.64** | **1.96** |
| **Lung** | **CT** | **14** | **10.86** | **1.29** |  | **18** | **2.38** | **7.56** |
| **Prostate** | **PSA** | **24** | **7** | **3.43** |  | **-** | **-** | **-** |
| **Breast** | **Combination of mammography, ultrasonography and physical examination** | **-** | **-** | **-** |  | **15** | **6.22** | **2.41** |

Available from Hamashima *et al*[18], 2006. O: Observed number; E: Expected number; CT: Computed tomography; PSA: Prostate specific antigen.


**Table 2 Sensitivities and specificities of endoscopy and radiography for gastric cancer screening**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Screening round** | **Method** | **Sensitivity** | **Specificity** | **Sensitivity** |
|  |  | **By the detection method** | **By the detection method** | **By the incidence method** |
| **Prevalence screening** | **Endoscopic screening** | **0.955** | **0.851** | **0.886** |
|  |  | **(95%CI: 0.875-0.991)** | **(95%CI: 0.843-0.859)** | **(95%CI: 0.698-0.976)** |
|  | **Radiographic screening** | **0.893** | **0.856** | **0.831** |
|  |  | **(95%CI: 0.718-0.977)** | **(95%CI: 0.846-0.865)** | **(95%CI: 0.586-0.964)** |
| **Incidence screening** | **Endoscopic screening** | **0.977** | **0.888** | **0.954** |
|  |  | **(95%CI: 0.919-0.997)** | **(95%CI: 0.883-0.892)** | **(95%CI: 0.842-0.994)** |
|  | **Radiographic screening** | **0.885** | **0.891** | **0.855** |
|  |  | **(95%CI: 0.664-0.972)** | **(95%CI: 0.885-0.896)** | **(95%CI: 0.637-0.970)** |


Available from Hamashima *et al*[23], 2006.

****


**Figure 1 Trends of breast cancer incidence before and after mammographic screenings in the United States.** A: Use of mammographic screening and incidence of stage-specific breast cancer among women 40 years of age and older; B: Incidence of stage-specific breast cancer among women younger than 40 years of age[12].

****

**Figure 2 Screen detection capability based on tumor biology and growth rates[13].** The growth rates of cancer vary and are divided into 4 categories: Rapid, slow, very slow, and non-progressive. Periodic screening detects slow-growing (Tumor B) and non-progressive (Tumor A) cancers early, and finds some progressive cancer (Tumor C) early. Tumor A remains undetectable and causes no morbidity during the patients’ lifetime without screening. However, rapid-growing cancer (Tumor D) which is a fatal tumor is not screened earlier and can cause death even with treatment.

****

**Figure 3 Estimation of frequency of overdiagnosis on the basis of the results of Malmö and Canadian studies.** The frequency of overdiagnosis was calculated on the basis of 2 randomized controlled trials for mammographic screening using 4 methods with different denominators as follows: A: Excess cancers as the frequency of cancers diagnosed over the whole follow-up period in unscreened women; B: Excess cancers as the frequency of cancers diagnosed over the whole follow-up period in women invited for screening; C: Excess cancers as the frequency of cancers diagnosed during the screening period in women invited for screening; D: Excess cancers as the frequency of cancers detected at screening in women invited for screening[16].

****

**Figure 4 A value framework for cancer screening.** The value of cancer screening strategies is linked to the screening intensity (population screened, frequency, and sensitivity of the test used) and is determined by the balance among benefits (*e.g*., cancer mortality reduction), harms (*e.g*., anxiety from false-positive test results, harms of diagnostic procedures, labeling, and overdiagnosis leading to overtreatment), and costs. The value of cancer screening is determined by a trade-off between benefits versus harms and costs. As the intensity increases, the benefits of screening rapidly increase. However, as the intensity increases beyond an optimal level, the increase in benefits slows down whereas harms and costs increase rapidly, and the value decreases[14].